References: Pre-exposure prophylaxis (PrEP) against HIV

  • Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM). Australian STI management guidelines for use in primary care. Sydney: ASHM; 2021. Accessed Oct 2023. https://sti.guidelines.org.au/
  • Brady M, Rodger A, Asboe D, Cambiano V, Clutterbuck D, Desai M, et al. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. HIV Med 2019;20 Suppl 2:s2-s80. https://www.ncbi.nlm.nih.gov/pubmed/30869189
  • Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381(9883):2083-90. https://www.ncbi.nlm.nih.gov/pubmed/23769234
  • Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 2022;399(10337):1779-89. https://www.ncbi.nlm.nih.gov/pubmed/35378077
  • Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med 2021;385(7):595-608. https://www.ncbi.nlm.nih.gov/pubmed/34379922
  • McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016;387(10013):53-60. https://www.ncbi.nlm.nih.gov/pubmed/26364263/
  • Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. New England Journal of Medicine 2015;373(23):2237-46. https://www.ncbi.nlm.nih.gov/pubmed/26624850
  • Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS 2013;27(13):2155-60. https://www.ncbi.nlm.nih.gov/pubmed/24384592
  • Riddell Jt, Amico KR, Mayer KH. HIV preexposure prophylaxis: A review. JAMA 2018;319(12):1261-8. https://www.ncbi.nlm.nih.gov/pubmed/29584848
  • Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(4):1-187. https://www.ncbi.nlm.nih.gov/pubmed/34292926